CSF1R and neoplasm: PLX-3397, a small molecule inhibitor of CSF1R, cKIT, and FLT3, has shown promise in reducing M2 macrophages and tumor burden when combined with adoptive cell transfer immunotherapy or other small molecule inhibitors.